A 55-year-old man with deficiency-pattern mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer is being conside...

Question

A 55-year-old man with deficiency-pattern mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer is being considered for first-line treatment. What targeted therapy is now recommended per NICE?

Accepted Answer

Pembrolizumab

Answer

Bevacizumab

Answer

Regorafenib

Answer

Trastuzumab

Answer

Cetuximab

uk-sce-gastroenterology MCQ (SBA): Colorectal Cancer

A 55-year-old man with deficiency-pattern mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer is being considered for first-line treatment. What targeted therapy is now recommended per NICE?